Immune response pathway via butyrate production

The term "Immune response pathway via butyrate production" does not refer to a single molecular target, receptor, enzyme, or protein. Instead, it describes a complex biological process in which butyrate, a short-chain fatty acid produced by gut bacteria from dietary fiber fermentation (notably Faecalibacterium prausnitzii and Eubacterium rectale/Roseburia spp.), modulates the host immune system[3]. Butyrate exerts its effects through several mechanisms: 1. Activation of specific G protein-coupled receptors—notably GPR41 (FFA3), GPR43 (FFA2), and GPR109A—expressed on intestinal epithelial cells and various immune cells[2][3]. 2. Inhibition of histone deacetylases (HDACs) in immune cells such as macrophages and B cells, leading to epigenetic changes that suppress pro-inflammatory gene expression[1][2][3][4]. 3. Modulation of cytokine production and B cell maturation through both direct epigenetic effects and indirect signaling pathways[1]. Butyrate's immunomodulatory actions are implicated in protection against inflammatory diseases like allergic asthma[1], improvement of intestinal barrier function[3], reduction in systemic inflammation associated with metabolic disorders[3], and possibly other conditions involving dysregulated immunity. Because this entry refers to an entire metabolic/immunological process rather than an individual druggable entity or canonical molecular target, it is considered incorrect for structured therapeutic targeting purposes. The correct approach would be to specify one of the key effectors within this pathway—such as "G protein-coupled receptor 43" or "Histone deacetylase"—as the actual therapeutic target if relevant for drug development efforts.

Other names

Butyrate pathwayShort-chain fatty acid immune modulationSCFA-mediated immune responseButyrate-GPCR/HDAC axis